NeuroXT, a Korean biotech company, announced on the 26th that it will strengthen its partnership with Beth Israel Deaconess Medical Center (BIDMC) at Harvard Medical School for joint research. NeuroXT’s primary goal is to verify the clinical efficacy of its “AI imaging biomarker solution,” which predicts treatment effects for Alzheimer’s patients. The company also plans to conduct research to contribute to the establishment of relevant treatment guidelines.

NeuroXT is focused on developing AI-based brain imaging biomarker analysis technology that can accurately predict the treatment effects of Alzheimer’s drugs for individual patients. This technology analyzes MRI results during the Alzheimer’s treatment planning stage. In particular, it focuses on predicting treatment effects based on the interaction between beta-amyloid and tau proteins, which are known to cause Alzheimer’s dementia. The core mechanism of this technology was published in the Neuron Journal, CELL’s  one of the world’s top three scientific journals, in 2022.

Seong Jun-kyung, CEO of NeuroXT, said, “We expect this technology to establish itself as the first imaging biomarker technology in the Alzheimer’s treatment market that can predict the suitability of treatment for individual patients. Furthermore, we expect it to provide significant future value to patients, medical professionals, pharmaceutical companies, and health insurance companies.”

He added, “Having passed the proof-of-concept (POC) stage through clinical trial data from global pharmaceutical companies, we are now on the verge of clinical validation using real-world patient data from a major U.S. hospital.”

To this end, NeuroXT has signed an agreement with BIDMC to jointly conduct clinical validation and develop personalized Alzheimer’s treatment guidelines. BIDMC is known as the first healthcare institution to be conditionally insured by the government’s Medicare. In particular, it operates the “DiAD (Disease Modifying Immunotherapies for the treatment of Alzheimer’s Disease)” clinic, a precision treatment center for Alzheimer’s. In addition, BIDMC’s Daniel Press is recognized as a leading authority in Alzheimer’s treatment. He served on the advisory committee for the FDA approval process of Eli Lilly’s Kesimpta drug in June and is currently leading the Alzheimer’s Precision Treatment Center at BIDMC.

Professor Daniel said, “Through this collaboration, we will lead the era of Alzheimer’s treatment.” He added, “I expect that we can establish a new paradigm for personalized dementia treatment based on treatment effect prediction through NeuroXT’s AI-based predictive biomarkers.”Since its founding in 2022, NeuroXT has secured seed investment from Aju IB Investment and Mira Ventures, and pre-Series A funding from Kakao Ventures, Daily Partners, Smilegate Investment, and Korea Investment Accelerator in 2023.